SIRDALUD 2MG 20TAB

Each tablet contains: Tizanidine 2 mg.

24.00 EGP

Purchase this product now and earn 24 Points!

SIRDALUD 2MG 20TAB; tizanidine, skeletal muscle relaxants .

ACTIVE-INGREDIENT OF SIRDALUD 2MG 20TAB

Each tablet contains: Tizanidine 2 mg.

INDICATION OF SIRDALUD 2MG 20TAB

Treatment of painful muscle spasms: associated with static and functional disorders of the spine (cervical and lumbar syndromes), following surgery, e.g. for herniated intervertebral disc or osteoarthritis of the hip. Treatment of spasticity due to neurological disorders: e.g. multible sclerosis, chronic myelopathy, degenerative spinal cord diseases, cerebrovascular accidents, and cerebral palsy.

DOSAGE OF SIRDALUD 2MG 20TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

Sirdalud has a narrow therapeutic index and a high inter-patient variability in tizanidine plasma concentrations which requires individualized dose adjustment. A low starting dose of 2 mg three times daily can minimize the risk for adverse effects. The dose should be carefully adjusted upward according to the needs of the individual patient. Relief of painful muscle spasms: The usual dose is 2 to 4 mg three times daily in tablet form. In severe cases, an extra dose of 2 or 4 mg may be taken, preferably at night to minimize sedation. Spasticity due to neurological disorders: The initial daily dose should not exceed 6 mg given in 3 divided doses. It may be increased stepwise at half-weekly or weekly intervals by 2 to 4 mg. The optimum therapeutic response is generally achieved with a daily dose of between 12 and 24 mg, administered in 3 or 4 equally spaced doses. The daily dose of 36 mg should not be exceeded. Special populations: Pediatric patients: Experience in patients below 18 years of age is limited and the use of Sirdalud in this population is not recommended. Geriatric patients (65 years of age or older): Experience with the use of Sirdalud in the elderly is limited. Therefore, it is recommended to start treatment at the lowest dose and increases should be done in small steps according to tolerability and efficacy. Renal impairment: In patients with renal impairment (creatinine clearance <25 mL/min), it is recommended to start treatment at 2 mg once daily. Increase in dosage should be done in small steps according to tolerability and efficacy. If efficacy has to be improved, It is advisable to first increase the strength of daily dose before increasing the frequency of administration. Hepatic impairment: Use of Sirdalud in patients with severe hepatic impairment is contraindicated. While Sirdalud is extensively metabolized in the liver limited data are available in this population. Its use has been associated with reversible abnormality in liver function tests. Sirdalud should be used with caution in patients with moderate hepatic impairment and treatment should be started with the lowest dose. Afterwards, increase in dosage should be done carefully and according to patient tolerability. Discontinuation of treatment: If Sirdalud has to be discontinued, the dosage should be slowely down titrated, particularly in patients who have received high doses for a longer period of time to avoid or minimize the risk of rebound hypertension and tachycardia.

OVER-DOSAGE OF SIRDALUD 2MG 20TAB

In the few reports of Sirdalud overdosage received, recovery was uneventful, including by a patient who ingested 400 mg Sirdalud. Syptoms: Nausea, vomiting, hypotension, QT©, prolongation, dizziness, somnolence, miosis, restlessness, respiratory distress, coma. Treatment: It is recommended to eliminate the ingested drug by repeated administration of high doses of activated charcoal. Forced diuresis is expected to accelerate the elimination of Sirdalud. Further treatment should be symptomatic.

CONTRA-INDICATION OF SIRDALUD 2MG 20TAB

Known hypersensitivity to tizanidine or to any of the excipients. Severely impaired function. Concomitant use of tizanidine with strong inhibitors of CYP1A2 such as fluvoxamine or ciprofloxacin is contraindicated.

STORAGE OF SIRDALUD 2MG 20TAB

Keep out of the reach of children. Do not store above 30 °C. should not be used after the date marked “EXP” on the pack. Should be kept out of the reach and sight of children.
PACK OF SIRDALUD 2MG 20TAB
20 tablets.
SIRDALUD 2MG 20TAB MANUFACTURED BY
Novartis Pharma S.A.E.,Cairo-C.C.R 111108-under licence from Novartis Pharma AG., Basle, Switzerland.

https://www.webmd.com/drugs/2/drug-1024/tizanidine-oral/details

https://www.gardeniapharmacy.com/category/medicine-2/

Form

How to use

1 review for SIRDALUD 2MG 20TAB

  1. abdo (verified owner)

    nice for muscle soreness

Add a review

Your email address will not be published.

Shopping Cart
Don`t copy text!
Scroll to Top